confirms that S3-antibody prevalence is significantly increased in persons with a wide variety of malignant disease, as well as in family members of patients with sarcoma.
WE HAVE PREVIOUSLY DETECTED (Sethi & Hirshaut, 1976 ) a tumour-associated antigen common to human sarcomas, using a complement-fixation assay. The prevalence of antibody to this antigen, S3, is markedly increased in persons with sarcoma, and to a lesser extent in patients with a wide variety of other solid tumours. When a group of patients with sarcoma was followed through surgery and their antibody levels to S3 determined before and after operation, sharp increases in antibody titres were observed after the removal of the tumour. Titres remained high in those with residual disease but gradually fell to undetectable levels in patients whose malignancy had been completely excised. These initial data suggest that the determination of changes in S3-antibody levels in sarcoma patients and others with malignancy might be of prognostic value.
This paper reports the results of additional studies to characterize the 83 antigen. Immunological techniques have been used to determine the heterogeneity of 83 preparations from different sources, and to discover whether S3 is related to previously identified antigens in benign and malignant tissues. Seroepidemiological studies have been completed to delineate more fully the distribution of S3 antibody.
MIATERIALS AND METHODS
Cell cultivation -Human sarcoma cells propagated in tissue culture are the source of 83 antigen. Details of procedures used for the establishment of sarcoma cell lines have been presented elsewhere (Sethi et al., 1977) . Cultured cells were maintained at 37TC in RPMI 1640 medium supplemented with 20% inactivated and filtered foetal calf serum. They were transferred and fed every 2-3 weeks. Cell lines were also checked periodically for mycoplasma by the method of Fogh et al. (1967) . Those used to prepare S3 were established to be free of such contamination.
Preparation of S3 antigen.-Test antigen was obtained from cultured cells harvested with a rubber policeman. Proteolytic enzymes were not used for cell dispersion. After washing the cells with phosphate-buffered saline (PBS) at pH 7*4, a 20% cell suspension was prepared in PBS. Cells were then frozen and thawed x 3 in liquid N2 and a 37°C water bath respectively. Cell membranes were additionally disrupted by sonication (Biosonic IV; VWR Scientific. San Francisco, California) for 2-3 min (10 sec/ml) in 1-min bursts. The crude suspension wAithout further centrifugation or filtration was the antigen source. This material wNas dispensed for storage into 1-ml polypropylene tubes kept in a freezer at -70°C.
Complement-fixationl assay.-In the test for S3, a standard microcomplement fixation method was used (Sever, 1962 To conduct the complement-fixation test, 0-025 ml VBS was delivered to each wNell in the plate. Serum was then added to the first horizontal row of Mwells, and serial 2-fold dilutions were made in a vertical direction with 0-025ml diluting loops. Every serum sample was diluted in du,plicate using adjacent vertical rows of wells. Then 2 units of antigen were placed in alternate vertical rowrs of wells and the remaining wells received a similar volume of VBS. Finally, two 100%-haemolytic units of complement were added to all wells, and the plates were incubated overnight in a plastic bag at 4°C. The next day, 0-05ml sensitized SRBC were added to each well. The haemolytic system was a 2%
suspension of 4-6-week-old washed SRBC. SRBC were sensitized by incubation with an equal volume of 1:800 diluted rabbit antiserum against SRBC (amboceptor) at 37°C for 30 min. The whole plate was again incubated at 37°C for 1 h with gentle intermittent shaking. Finally each plate was centrifuged for 5 mnim-at 1000 rev/min and readings were taken. Sera giving a 2+ reaction or greater at a dilution of 1: 4 or above, and free of anticomplementary activity, were considered positive for S3 antibody. Absorption procedures. Sera to be studied were inactivated at 56°C for 30 min. They were then diluted A-ith VBS to twice their limiting positive dilution. One aliquot remained unabsorbed while other aliquots A-ere mixed -with an equal volume of absorbing material. All samples were gently shaken for 3 min and then stored at 4°C overnight. The next day, after centrifugation at 2000 rev/ min for 15 min, supernatants were removed by pipette and tested against a standard S3 preparation in a complement-fixation assay. ITnabsorbed serum wAas run as a control with each assay. Absorbants included S3 antigen preparation, boiled beef (BB), guinea-pig kidney (GPK), sheep red blood cells (SRBC), Type A and B RBC an-d carcinoembryonic antigen (CEA).
Other assays. CEA and a-fetoprotein (AFP) levels -were measured by radioimmunoassay (RIA) using techniques previously described (Hansen et al., 1971 : W\aldman & Mclntire, 1972 . These tests wvere performed respectively in the laboratories of Drs Morton Sch-wartz and Thomas Waldmann. Anti-Epstein-Barr Virus (EBV) viral capsid antigen (VCA) titres were performed by the method of Hirshaut et al. (1969) .
RESULTS
The cell lines used for S3 preparations are presented in Table I . To compare S3 To confirm previous observations about the seroepidemiology of S3 antibody, the number of patients studied has been increased, and now includes 378 with a variety of malignancies and 54 controls (Table VIII) . Patients with sarcoma con- Characterization of S3 requires preparation of large quantities of antigen. Unfortunately, it is difficult to predict whether a given passage of a human sarcoma cell line will contain detectable S3 . This places practical limits on the size of any single culture passage prepared from different passages of the same lines and from different lines. It is therefore particularly important that S3 antigen prepared from several cell lines has been found to be immunologically identical.
The complete absorption of S3 antibody from test sera by GPK, but not SRBC or BB, establishes S3 as a new heterophile antigen distinct from the well known heterophile substances associated with SRBC, such as Forssman, infectious mononucleosis and serum-sickness antigens. The availability of a second source of S3, GPK, will also be of assistance in characterization studies. This may be particularly important for biochemical isolation which requires large volumes of starting materials.
Heterophile antigens related to SRBC (particularly Forssman antigen) may be expressed more frequently by malignant than normal tissues (Milgrom et al., 1973) . Increased heterophile antibody titres have been reported in patients with Hodgkin's disease (Kasukawa et al., 1976) , sarcoma (Feit et al., 1977) and other neoplastic diseases (Southam et al., 1951) . They are decreased in carcinoma of the lung (Kitamura et al., 1979) . Another sarcoma antigen discovered in this laboratory, Si (Hirshaut et al., 1974) , has also recently been shown to be a heterophile substance not found on SRBC. Si antibody prevalence is consistently higher in patients with malignancy. We have now identified S3 antibody as another heterophile antibody the prevalence of which is increased in cancer patients.
The presence of CEA and AFP in some S3 antigen preparations and S3 antisera makes it mandatory to distinguish these from S3. The lack of any relationship between the presence of these two well characterized tumour antigens and S3 antigen or antibody titres makes it unlikely that there is any cross-reactivity. For CEA this is confirmed by the inability of purified CEA to absorb S3 antibody.
While the highest prevalence of S3 antibody has so far been found in patients with sarcoma, the expanded seroepidemiologic investigation confirms that patients with a wide variety of malignant diseases have an increased prevalence of antibody to S3, as do family members of those with sarcoma. This lack of specificity precludes the use of an S3 assay for diagnosis. However, the increased prevalence of antibody in persons with so many different neoplastic diseases implies that changes in S3 antibody levels may be of prognostic value in patients with a variety of malignant conditions.
